Purple Biotech Ltd expected to post a loss of 34 cents a share - Earnings Preview

Reuters02-27

<a href="https://laohu8.com/S/PPBT">Purple Biotech</a> Ltd <ppbt.oq> expected to post a loss of 34 cents a share - Earnings Preview </ppbt.oq>

Purple Biotech Ltd PPBT.OQ, PPBT.O is expected to show no change in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Purple Biotech Ltd is for a loss of 34 cents per share.
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 6,727.3% above its last closing price of $0.50

This summary was machine generated February 27 at 12:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614752858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614752858","market":"nz","top_or_hot":-1,"title":"Purple Biotech Ltd  expected to post a loss of 34 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PPBT\">Purple Biotech</a> Ltd <ppbt.oq> expected to post a loss of 34 cents a share - Earnings Preview </ppbt.oq></title></head><body><ul><li><p>Purple Biotech Ltd <span>PPBT.OQ</span>, <span>PPBT.O</span> is expected to  show no change in quarterly revenue when it reports  results on March 3 (estimated) for the period ending December 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Purple Biotech Ltd is for a loss of 34 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is also \"Buy\".</p></li><li><p>Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 6,727.3% above its last closing price of $0.50</p></li></ul><p>This summary was machine generated February 27 at 12:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Purple Biotech Ltd  expected to post a loss of 34 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPurple Biotech Ltd  expected to post a loss of 34 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-27 20:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PPBT\">Purple Biotech</a> Ltd <ppbt.oq> expected to post a loss of 34 cents a share - Earnings Preview </ppbt.oq></title></head><body><ul><li><p>Purple Biotech Ltd <span>PPBT.OQ</span>, <span>PPBT.O</span> is expected to  show no change in quarterly revenue when it reports  results on March 3 (estimated) for the period ending December 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Purple Biotech Ltd is for a loss of 34 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is also \"Buy\".</p></li><li><p>Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 6,727.3% above its last closing price of $0.50</p></li></ul><p>This summary was machine generated February 27 at 12:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN1CE:1","article_id":"2614752858","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614752858","pubTimestamp":1772194693,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Purple Biotech Ltd  expected to post a loss of34cents a share - Earnings Preview Purple Biotech Ltd PPBT.OQ, PPBT.O is expected to  show no change in quarterly revenue when it reports  results on Marc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PPBT":"Purple Biotech Ltd."},"translate_title":"Purple Biotech Ltd预计每股亏损34美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PPBT":0.9},"content_text":"Purple Biotech Ltd  expected to post a loss of 34 cents a share - Earnings Preview Purple Biotech Ltd PPBT.OQ, PPBT.O is expected to  show no change in quarterly revenue when it reports  results on March 3 (estimated) for the period ending December 31 2025LSEG's mean analyst estimate for Purple Biotech Ltd is for a loss of 34 cents per share. The one available analyst rating on the shares is \"buy\".  The average consensus recommendation for the biotechnology & medical research peer group is also \"Buy\".Wall Street's median 12-month price target for Purple Biotech Ltd is $34.00, about 6,727.3% above its last closing price of $0.50This summary was machine generated February 27 at 12:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614752858","isCrawlerRequest":true}